atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Map My Mole, by Community Dermatology Limited, is a service that offers remote assessments of moles and skin lesions by consultant dermatologists.
Their missions in to bring skin checks to where the patient is, whether at home or in one…
Working in collaboration with partners across health and care, its multi-disciplinary team carries out health technology assessments of health or care technologies that are not a medicine and publishes national guidance on their use in Wales.
Read more here.
Attendees
Sponsors and
Exhibitors
Webinars
Contact us